Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Lapatinib may stop the growth of tumor cells by blocking the enzymes necessary for their
growth. Phase II trial to study the effectiveness of lapatinib in treating patients who have
recurrent or metastatic prostate cancer.